CEMI Key Statistics, Chart & Performance
The current stock price of CEMI is 0.455 USD. In the past month the price increased by 5.79%. In the past year, price decreased by -20.97%.
CEMI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CEMI. When comparing the yearly performance of all stocks, CEMI is one of the better performing stocks in the market, outperforming 82.43% of all stocks.
CEMI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CEMI. CEMI may be in some trouble as it scores bad on both profitability and health.
CEMI Financial Highlights
Over the last trailing twelve months CEMI reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 45.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CEMI Forecast & Estimates
6 analysts have analysed CEMI and the average price target is 8.16 USD. This implies a price increase of 1693.41% is expected in the next year compared to the current price of 0.455.
CEMI Ownership
CEMI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.84 | 15.925B | ||
| SOLV | SOLVENTUM CORP | 12.03 | 13.352B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.42 | 12.601B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 19.69 | 4.721B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.37 | 4.301B | ||
| ICUI | ICU MEDICAL INC | 18.41 | 3.695B | ||
| HAE | HAEMONETICS CORP/MASS | 11.22 | 3.044B | ||
| XRAY | DENTSPLY SIRONA INC | 8.55 | 2.5B | ||
| NEOG | NEOGEN CORP | 32.38 | 2.301B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.41 | 1.975B |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CEMI
Company Profile
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. The company is headquartered in Medford, New York and currently employs 188 full-time employees. The company went IPO on 2000-10-18. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. The company is also targeting lateral flow test solutions for infectious diseases.
Company Info
CHEMBIO DIAGNOSTICS INC
555 Wireless Blvd, 3661 Horseblock Road
Medford NEW YORK 11788 US
CEO: Richard L. Eberly
Employees: 188
Phone: 16319241135.0
CHEMBIO DIAGNOSTICS INC / CEMI FAQ
What does CHEMBIO DIAGNOSTICS INC do?
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. The company is headquartered in Medford, New York and currently employs 188 full-time employees. The company went IPO on 2000-10-18. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. The company is also targeting lateral flow test solutions for infectious diseases.
Can you provide the latest stock price for CHEMBIO DIAGNOSTICS INC?
The current stock price of CEMI is 0.455 USD. The price increased by 0.22% in the last trading session.
What is the dividend status of CHEMBIO DIAGNOSTICS INC?
CEMI does not pay a dividend.
What is the ChartMill technical and fundamental rating of CEMI stock?
CEMI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for CHEMBIO DIAGNOSTICS INC?
CHEMBIO DIAGNOSTICS INC (CEMI) has a market capitalization of 16.71M USD. This makes CEMI a Nano Cap stock.
What is the next earnings date for CEMI stock?
CHEMBIO DIAGNOSTICS INC (CEMI) will report earnings on 2023-05-09.
What is the ownership structure of CHEMBIO DIAGNOSTICS INC (CEMI)?
You can find the ownership structure of CHEMBIO DIAGNOSTICS INC (CEMI) on the Ownership tab.